In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex | Zendy

Barbara A. BrownElliott | Zendy; Julie V. Philley | Zendy; David E. Griffith | Zendy; Foram Thakkar | Zendy; Richard J. Wallace | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

In Vitro Susceptibility Testing of Bedaquiline against Mycobacterium avium Complex

Author(s) -

Barbara A. BrownElliott,

Julie V. Philley,

David E. Griffith,

Foram Thakkar,

Richard J. Wallace

Publication year - 2016

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01798-16

Subject(s) - bedaquiline , broth microdilution , microbiology and biotechnology , mycobacterium avium complex , mycobacterium , biology , mycobacterium tuberculosis , in vitro , medicine , antibiotics , tuberculosis , minimum inhibitory concentration , pathology , biochemistry

We performed bedaquiline broth microdilution susceptibility testing using Clinical and Laboratory Standards Institute (CLSI) guidelines on 103 respiratory isolates of Mycobacterium avium complex (MAC), including multidrug-resistant isolates. Approximately 90% of isolates had bedaquiline MICs of ≤0.008 μg/ml, and 102/103 isolates had MICs of ≤0.015 μg/ml. Bedaquiline has excellent potential for use in patients with MAC infections, although for reasons of its metabolism by the cytochrome P450 system, it should not be given with rifampin.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research